Scott D. Lunin

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ian W. Flinn, Peter Hillmen, Marco Montillo et al. · Blood · 2018 · 341 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Ian W. Flinn, Carole B. Miller, Kirit M. Ardeshna et al. · Journal of Clinical Oncology · 2019 · 264 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

Guillermo Garcia‐Manero, Gail J. Roboz, Katherine Walsh et al. · The Lancet Haematology · 2019 · 93 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

Gail J. Roboz, Hagop M. Kantarjian, Karen Yee et al. · Cancer · 2017 · 66 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Identification of overlapping epitopes in mutant <i>ras</i> oncogene peptides that activate CD4⁺ and CD8⁺ T cell responses

Scott I. Abrams, Stephen F. Stanziale, Scott D. Lunin et al. · European Journal of Immunology · 1996 · 60 citations · Full text

Life Sciences, Immunology, Oncology +17